Opinion|Videos|September 6, 2023
Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL
Author(s)Jae Park, MD
Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.
Advertisement
Episodes in this series
Advertisement
Related to this article
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
3
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
4
Dr Graham on Data for JNJ-87189401 Plus Pasritamig in mCRPC
5